Ethicon, a surgical products developer owned by Johnson & Johnson, antimicrobial dressing Biopatch has been included in the NHS Catalogue of Potential Innovations as it has been found to reduce catheter-related blood stream infections (CRBSI) by up to 69%.
The antimicrobial dressing, which comes with chlorhexidine gluconate (CHG), is helpful in reducing infections of local nature, CRBSI, and colonisation of microorganisms on skin, commonly due to CRBSI, in patients with either central venous or arterial catheters.
The catalogue noted that Biopatch kills most of the common pathogens like methicillin-resistant staphylococcus aureus and methicillin-sensitive staphylococcus aureus.
Biopatch helps in preventing patients from premature death, recovering from series of ill-health and provides a positive and safe experience of treatment, meeting the basic requirements of the NHS, the catalogue pointed out.
Biopatch UK, Ireland, Nordics business manager Andrew Cleworth said that some hospitals are saving hundreds of thousands of pounds, simply by reducing their CRBSI rates with the implementation of Biopatch as part of their bundle of care.
"Our aim is always to ensure that hospital CRBSI rates are further reduced and that we contribute to improving patient outcomes," Cleworth added.
Non-usage of Biotech could result in quick recolonisation of resident bacteria on the skin’s surface even after antiseptic applications.
Biopatch, through hydrophilic foam matrix, gradually releases antimicrobial and antifungal CHG , which stops catheter-related blood stream infections and skin colonisation of microorganisms due to CRBSI.
Latest figures from the National Institute for Health and Care Excellence (NICE) indicate that every year 300,000 patients suffer from healthcare acquired infections, of which 54,000 or roughly 18% of the patients suffer from CRBSIs.
England’s chief medical officer Professor Dame Sally Davies, in a report on the issues of infection and antimicrobial infections, noted: "It is essential that we continue to develop our defences against infectious disease and to do this we must align policy, science, innovation and clinical excellence."
Claimed to be the only device of its kind with an FDA cleared indication to reduce local infections, the company has cautioned against the usage of this device on premature infants, as it has resulted in hypersensitivity reactions and necrosis of the skin.